Praxis Precision Medicines, Inc. (PRAX)
Free
No email, no account, no signup.
Pulling latest news for Praxis Precision Medicines, Inc.…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report –
Order analysis – $4.99 $1.25
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
CNS precision neuroscience biotechnology
Market Cap
$7.1B
We're already tracking Praxis Precision Medicines, Inc. — here are the latest events we've registered
Recent News
- On June 1, 2026, the company announced that its Phase 2/3 POWER1 study of vormatrigine for focal onset seizures did not meet its primary endpoint. Consequently, enrollment in the subsequent POWER2 study has been paused to reassess the program's path forward. Meanwhile, the company is progressing with commercial preparations for ulixacaltamide and relutrigine following FDA acceptance of their New Drug Applications.
Want to know how this news affects Praxis Precision Medicines, Inc.? Order the analysis.
Order analysis – What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Sources: news, filings, market data, and investor forums
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Praxis Precision Medicines, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.